Browse by Series:

FDA Approvals in CLL and ALL, NDA Accepted in Melanoma, and More

Gina Columbus
Published: Thursday, Sep 08, 2016



Gina Columbus reports on FDA approvals for blinatumomab in acute lymphoblastic leukemia and ofatumumab in chronic lymphocytic leukemia, encouraging phase III findings with atezolizumab in lung cancer, acceptance of a new drug application for binimetinib in melanoma, and a European approval for crizotinib in lung cancer.
Slider Left
Slider Right


Gina Columbus reports on FDA approvals for blinatumomab in acute lymphoblastic leukemia and ofatumumab in chronic lymphocytic leukemia, encouraging phase III findings with atezolizumab in lung cancer, acceptance of a new drug application for binimetinib in melanoma, and a European approval for crizotinib in lung cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x